{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:21:45Z","timestamp":1708474905868},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,20]]},"DOI":"10.7759\/cureus.54503","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T08:05:30Z","timestamp":1708416330000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Treatment Strategies for Male Prolactin-Secreting Pituitary Neuroendocrine Tumors"],"prefix":"10.7759","author":[{"given":"Norihiko","family":"Saito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomi","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Koyahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Hiramoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruo","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morito","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Iwabuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam MP","year":"2006","unstructured":"Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006, 27:485-534. 10.1210\/er.2005-9998","journal-title":"Endocr Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1997.tb02196.x","article-title":"Hyperprolactinaemia in males: a heterogeneous disorder","volume":"27","author":"Walsh JP","year":"1997","unstructured":"Walsh JP, Pullan PT. Hyperprolactinaemia in males: a heterogeneous disorder. Aust N Z J Med. 1997, 27:385-90. 10.1111\/j.1445-5994.1997.tb02196.x","journal-title":"Aust N Z J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1385\/ENDO:20:1-2:75","article-title":"Hyperprolactinemia in men: clinical and biochemical features and response to treatment","volume":"20","author":"De Rosa M","year":"2003","unstructured":"De Rosa M, Zarrilli S, Di Sarno A, et al.. Hyperprolactinemia in men: clinical and biochemical features and response to treatment. Endocrine. 2003, 20:75-82. 10.1385\/ENDO:20:1-2:75","journal-title":"Endocrine"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-014-0563-z","article-title":"Hypopituitarism patterns and prevalence among men with macroprolactinomas","volume":"18","author":"Tirosh A","year":"2015","unstructured":"Tirosh A, Benbassat C, Lifshitz A, Shimon I. Hypopituitarism patterns and prevalence among men with macroprolactinomas. Pituitary. 2015, 18:108-15. 10.1007\/s11102-014-0563-z","journal-title":"Pituitary"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-005-5084-3","article-title":"PRL secreting adenomas in male patients","volume":"8","author":"Ciccarelli A","year":"2005","unstructured":"Ciccarelli A, Guerra E, De Rosa M, Milone F, Zarrilli S, Lombardi G, Colao A. PRL secreting adenomas in male patients. Pituitary. 2005, 8:39-42. 10.1007\/s11102-005-5084-3","journal-title":"Pituitary"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-06-0646","article-title":"Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men","volume":"156","author":"Shimon I","year":"2007","unstructured":"Shimon I, Benbassat C, Hadani M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol. 2007, 156:225-31. 10.1530\/EJE-06-0646","journal-title":"Eur J Endocrinol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.40.857","article-title":"Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients","volume":"40","author":"Sabuncu T","year":"2001","unstructured":"Sabuncu T, Arikan E, Tasan E, Hatemi H. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Intern Med. 2001, 40:857-61. 10.2169\/internalmedicine.40.857","journal-title":"Intern Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030979","article-title":"Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis","volume":"89","author":"Colao A","year":"2004","unstructured":"Colao A, Vitale G, Cappabianca P, et al.. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab. 2004, 89:1704-11. 10.1210\/jc.2003-030979","journal-title":"J Clin Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-019-01009-y","article-title":"Prolactinomas in males: any differences?","volume":"23","author":"Duskin-Bitan H","year":"2020","unstructured":"Duskin-Bitan H, Shimon I. Prolactinomas in males: any differences?. Pituitary. 2020, 23:52-7. 10.1007\/s11102-019-01009-y","journal-title":"Pituitary"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01770.x","article-title":"Giant prolactinomas in men: efficacy of cabergoline treatment","volume":"58","author":"Corsello SM","year":"2003","unstructured":"Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA, Colosimo C. Giant prolactinomas in men: efficacy of cabergoline treatment. Clin Endocrinol (Oxf). 2003, 58:662-70. 10.1046\/j.1365-2265.2003.01770.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2012.04351.x","article-title":"Prolactinomas in men: a multicentre and retrospective analysis of treatment outcome","volume":"77","author":"Iglesias P","year":"2012","unstructured":"Iglesias P, Bernal C, Villabona C, Castro JC, Arrieta F, D\u00edez JJ. Prolactinomas in men: a multicentre and retrospective analysis of treatment outcome. Clin Endocrinol (Oxf). 2012, 77:281-7. 10.1111\/j.1365-2265.2012.04351.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-011-9462-5","article-title":"Vertebral fractures in males with prolactinoma","volume":"39","author":"Mazziotti G","year":"2011","unstructured":"Mazziotti G, Porcelli T, Mormando M, et al.. Vertebral fractures in males with prolactinoma. Endocrine. 2011, 39:288-93. 10.1007\/s12020-011-9462-5","journal-title":"Endocrine"},{"key":"ref13","article-title":"Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas","volume":"131","author":"Bhansali A","year":"2010","unstructured":"Bhansali A, Walia R, Dutta P, Khandelwal N, Sialy R, Bhadada S. Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas. Indian J Med Res. 2010, 131:530-5.","journal-title":"Indian J Med Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.22.6.0451","article-title":"Dopamine as a prolactin (PRL) inhibitor","volume":"22","author":"Ben-Jonathan N","year":"2001","unstructured":"Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001, 22:724-63. 10.1210\/edrv.22.6.0451","journal-title":"Endocr Rev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-005-1111-8","article-title":"Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists","volume":"111","author":"Kontogeorgos G","year":"2006","unstructured":"Kontogeorgos G, Horvath E, Kovacs K, Coire C, Lloyd RV, Scheithauer BW, Smyth HS. Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists. Acta Neuropathol. 2006, 111:46-52. 10.1007\/s00401-005-1111-8","journal-title":"Acta Neuropathol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-63-2-383","article-title":"Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and nonfunctioning macroadenomas of the pituitary gland","volume":"63","author":"Esiri MM","year":"1986","unstructured":"Esiri MM, Bevan JS, Burke CW, Adams CB. Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and nonfunctioning macroadenomas of the pituitary gland. J Clin Endocrinol Metab. 1986, 63:383-8. 10.1210\/jcem-63-2-383","journal-title":"J Clin Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2000.00901.x","article-title":"CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas","volume":"52","author":"Leong KS","year":"2000","unstructured":"Leong KS, Foy PM, Swift AC, Atkin SL, Hadden DR, MacFarlane IA. CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas. Clin Endocrinol (Oxf). 2000, 52:43-9. 10.1046\/j.1365-2265.2000.00901.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.11.8054","article-title":"Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy","volume":"86","author":"Di Sarno A","year":"2001","unstructured":"Di Sarno A, Landi ML, Cappabianca P, et al.. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab. 2001, 86:5256-61. 10.1210\/jcem.86.11.8054","journal-title":"J Clin Endocrinol Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0236","article-title":"Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients","volume":"167","author":"Vroonen L","year":"2012","unstructured":"Vroonen L, Jaffrain-Rea ML, Petrossians P, et al.. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol. 2012, 167:651-62. 10.1530\/EJE-12-0236","journal-title":"Eur J Endocrinol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005833","article-title":"Surgical treatment for male prolactinoma: a retrospective study of 184 cases","volume":"96","author":"Song YJ","year":"2017","unstructured":"Song YJ, Chen MT, Lian W, Xing B, Yao Y, Feng M, Wang RZ. Surgical treatment for male prolactinoma: a retrospective study of 184 cases. Medicine (Baltimore). 2017, 96:e5833. 10.1097\/MD.0000000000005833","journal-title":"Medicine (Baltimore)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.14310\/horm.2002.1729","article-title":"Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review","volume":"16","author":"Almalki MH","year":"2017","unstructured":"Almalki MH, Aljoaib NN, Alotaibi MJ, Aldabas BS, Wahedi TS, Ahmad MM, Alshahrani F. Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review. Hormones (Athens). 2017, 16:139-49. 10.14310\/horm.2002.1729","journal-title":"Hormones (Athens)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2016.10.059","article-title":"Long-term follow-up of primary medical versus surgical treatment of prolactinomas in men: effects on hyperprolactinemia, hypogonadism, and bone health","volume":"97","author":"Andereggen L","year":"2017","unstructured":"Andereggen L, Frey J, Andres RH, El-Koussy M, Beck J, Seiler RW, Christ E. Long-term follow-up of primary medical versus surgical treatment of prolactinomas in men: effects on hyperprolactinemia, hypogonadism, and bone health. World Neurosurg. 2017, 97:595-602. 10.1016\/j.wneu.2016.10.059","journal-title":"World Neurosurg"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/231063-evaluation-of-treatment-strategies-for-male-prolactin-secreting-pituitary-neuroendocrine-tumors","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T08:05:34Z","timestamp":1708416334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/231063-evaluation-of-treatment-strategies-for-male-prolactin-secreting-pituitary-neuroendocrine-tumors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.54503","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,20]]}}}